OBJECTIVE: To determine the range of plasma @entity1255 values in a cohort of type 1 @entity6 subjects and to analyse the relationship between @entity1255 levels and @entity179 . MATERIAL AND METHODS: 71 type 1 @entity6 inpatients admitted for poor @entity532 , especially macroangiopathic, were included in this study. Chronic @entity2412 , smoking prevalence, as well as current use of drugs were recorded, alongside fasting plasma @entity1255 . RESULTS: Age and @entity6 duration were 51 (34-63) and 23 (13-32) years respectively (median [percentile 25-75]). HbA(1)c was 9.3% (8.2-10.5). @entity1255 was 9.2 (7.1-13.6) micromol/l, and 17% of @entity1 had elevated homocysteinaemia on the basis of a laboratory cutoff value of 15 micromol/l. @entity1501 and @entity2186 levels were within the normal range. Univariate statistical analysis showed a significant positive association between @entity1255 and age (P<0.001), @entity6 duration (P<0.001), systolic blood pressure (P<0.001), plasma @entity1011 (P<0.001), @entity165 /HDL-C (P=0.021) as well as with @entity989 (P=0.016) and all complications (P<0.001), and a negative correlation with @entity1501 (P=0.004) and @entity1011 clearance (P<0.001). Using a multiple regression analysis taking into account major variables, we confirmed an independent association of @entity1255 with age (P=0.003), @entity1011 (P<0.001) and @entity1501 (P=0.014), but not with @entity455 . CONCLUSIONS: Increased @entity1255 is present in 17% of a limited group of poorly controlled type 1 @entity6 @entity1 , and is associated with age, @entity1011 and @entity1501 levels. In this type 1 population, there was no independent correlation of @entity1255 with @entity455 , in particular macroangiopathy.

Micro- and macrovascular complications and hyperhomocysteinaemia in type 1 @entity6 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid', 'Folic acid'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular complications'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine', 'Homocysteine'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy'] @entity532 :: ('MESH:D003925', 'Disease') :: ['glycaemic control and/or treatment of complications'] @entity2186 :: ('MESH:D014805', 'Chemical') :: ['vitamin B(12)'] @entity179 :: ('MESH:D019636', 'Disease') :: ['chronic degenerative complications'] @entity2412 :: ('MESH:D048909', 'Disease') :: ['diabetic complications'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1 :: (9606,Species) :: ['patients']
